# Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

> **NCT00535119** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 107 (actual)

## Conditions studied

- Adult Solid Neoplasm
- BRCA1 Mutation Carrier
- BRCA2 Mutation Carrier
- Hereditary Breast and Ovarian Cancer Syndrome

## Interventions

- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacological Study
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT00535119
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-10
- **Final completion:** —
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2015-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535119, "Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00535119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*